Currently, four drugs have been approved by the Federal Drug Administration for treating cognitive impairment in AD, including three cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and one NMDA receptor antagonist (Memantine). This evidence concerns the gene BCHE and Alzheimer disease.